Unity Biotechnology, Inc.

NASDAQ:UBX

1 (USD) • At close December 24, 2024
Bedrijfsnaam Unity Biotechnology, Inc.
Symbool UBX
Munteenheid USD
Prijs 1
Beurswaarde 16,850,400
Dividendpercentage 0%
52-weken bereik 0.947 - 2.02
Industrie Biotechnology
Sector Healthcare
CEO Dr. Anirvan Ghosh Ph.D.
Website https://unitybiotechnology.com

An error occurred while fetching data.

Over Unity Biotechnology, Inc.

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular

Vergelijkbare Aandelen

Pulse Biosciences, Inc. logo

Pulse Biosciences, Inc.

PLSE

18.33 USD

Biodesix, Inc. logo

Biodesix, Inc.

BDSX

1.46 USD

89bio, Inc. logo

89bio, Inc.

ETNB

7.94 USD

Cryo-Cell International, Inc. logo

Cryo-Cell International, Inc.

CCEL

7.75 USD

Purple Biotech Ltd. logo

Purple Biotech Ltd.

PPBT

3.82 USD

Biotricity, Inc. logo

Biotricity, Inc.

BTCY

0.282 USD

Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc.

CRDF

3.92 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)